98%
921
2 minutes
20
Objective: Government inquiries present a policy window for advocates to influence policy. Evidence on how to write influential submissions, however, is sparse. We aimed to identify features of successful written submissions to the Parliament of Australia's Inquiry into Food Pricing and Food Security in Remote Indigenous Communities (Inquiry).
Method: A scoping review was conducted to identify influential features of written submissions to government inquiries. A content analysis of a sub-sample of government Inquiry submissions and their recommendations was then coded for influential features. The frequency of submission recommendations incorporated into the final Inquiry report was recorded, as was their link to influential features.
Results: Thirty features were identified. Results from 21 submissions indicate that when writing a submission to a government inquiry, advocates should: (1) ensure their submission is clear and concise; (2) convey the authority of both the writer and supporting evidence; and (3) where possible, align submission recommendations with the government agenda.
Conclusions: We encourage future research to test the framework of influential features on other inquiry topics and in other countries to increase the reliability of results.
Implications For Public Health: This study consolidates and presents a list of features that advocates can consider incorporating when writing a submission to a government inquiry.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.anzjph.2024.100133 | DOI Listing |
Front Hum Neurosci
September 2025
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, United States.
Primary progressive aphasia (PPA) is a neurological syndrome characterized by the gradual deterioration of language capabilities. Due to its neurodegenerative nature, PPA is marked by a continuous decline, necessitating ongoing and adaptive therapeutic interventions. Recent studies have demonstrated that behavioral therapies, particularly when combined with neuromodulation techniques such as transcranial direct current stimulation (tDCS), can improve treatment outcomes, including the long-term maintenance and generalization of therapeutic effects.
View Article and Find Full Text PDFActa Psychol (Amst)
September 2025
Department of Kinesiology, College of Health and Human Sciences, Kansas State University, Manhattan, KS 66506, United States.
Background: Using height-adjustable stand-up (stand-up) desks within classrooms for students with emotional disturbances may be beneficial for reducing sedentary behavior and promoting positive classroom behaviors.
Aims: To investigate the feasibility and acceptability of stand-up desks for students with emotional disturbances and determine the preliminary effects of stand-up desks on sedentary time (SED), physical activity (PA), and classroom behaviors.
Methods And Procedures: Four participants aged 12-14 years alternated using traditional or stand-up desks in a 10-week crossover design across one school year.
BMC Health Serv Res
September 2025
Centre for Health Policy, University of Melbourne, Parkville, Melbourne, VIC, 3052, Australia.
Background: Digital Coordination Centres (DCCs) represent an innovative approach in hospital settings, designed to enhance patient flow, operational efficiency, and real-time decision-making. While their potential is widely recognised, there is limited understanding of the factors influencing their implementation. This study evaluated the implementation of a DCC in a large Australian hospital, with a focus on identifying enablers, barriers, and strategies for improvement.
View Article and Find Full Text PDFAm J Clin Dermatol
September 2025
Department of Dermatology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Background: Upadacitinib is an oral selective Janus kinase inhibitor approved to treat moderate-to-severe atopic dermatitis (AD) in adults and adolescents; long-term efficacy and safety data beyond 1 year are needed.
Objective: The aim was to evaluate the long-term efficacy and safety of upadacitinib treatment through 140 weeks in patients with moderate-to-severe AD.
Methods: Measure Up 1 (MeUp1; NCT03569293), Measure Up 2 (MeUp2; NCT03607422), and AD Up (NCT03568318) are ongoing, phase 3, randomized clinical trials evaluating upadacitinib 15 mg (UPA15) and 30 mg (UPA30) in adults and adolescents with moderate-to-severe AD.